Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, announced its support for the Genomic Answers for Children’s Health Act. This legislation, introduced in the ...

In this GEN webinar, Guilherme Yamamoto, MD, PhD, and Sevana Yaghoubian will present a novel whole-exome assay for detecting high-confidence variants across multiple applications.

Detailed price information for Genedx Holdings Corp (WGS-Q) from The Globe and Mail including charting and trades.

Labcorp , a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians ...

GeneDx stock (NASDAQ: WGS) plunged 14% on Monday after the genomics testing company released preliminary full-year 2025 results that met expectations. But the company unveiled 2026 guidance that ...

Investing.com -- GeneDx Holdings Corp (NASDAQ:WGS) stock fell 14% Monday after the genomic testing company’s 2026 guidance failed to impress investors despite reporting solid preliminary results for ...

GeneDx reported full-year 2025 revenue of approximately $427M, inline with consensus of $427M, representing a 41% year-over-year increase and within its previously raised guidance range of $425 ...

Genedx Holding Corp. launched Genomedx Prenatal, its whole genome sequencing test, to provide more definitive diagnoses of the causes of fetal abnormalities identified by ultrasound. By combining the ...

Background: Congenital heart disease is among the most prevalent birth defects. This study aims to evaluate the clinical utility of chromosome microarray analysis (CMA) and whole-exome sequencing (WES ...